spacer
home > epc > summer 2018 > a blemish on good science
PUBLICATIONS
European Pharmaceutical Contractor

A Blemish on Good Science

In scientific research, objective data collection is critical to making conclusions that are free from bias. The importance of minimising subjectivity is particularly important in dermatology clinical trials where clinically acceptable methods of assessing disease symptoms or treatment response are largely based on a physician’s subjective assessment.

Dermatologists assess skin lesions and treatment responses using different observer-rated scales, such as the Eczema Area and Severity Index (EASI) and the Psoriasis Area and Severity Index (PASI). Both rely on visual assessments of symptoms, such as erythema (redness). This traditional approach of ‘eye-balling lesions’ results in subjective measurements prone to inter- and intra-observer variability (1). They can even vary at different times of the day.

Developing processes to objectively measure outcomes in dermatology clinical trials should be a priority for sponsors and investigators in this field. Thought leaders, including Dr James Milbauer, believe that, in the not-too-distant future, imaging technology and software will enable clinicians to scan, measure, and objectively assess patients and clinical trial participants (2). Until this technology becomes a reality, the pharmaceutical industry will continue to rely on alternative established strategies to mitigate the current lack of objectivity in measuring outcomes for dermatology trials. This article will discuss these strategies and the research that has created the first steps towards objective measurements for dermatology trials.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr Elisabeth Rowold, Director of Project Management in the dermatology division (Europe), has more than 23 years of experience in the pharma industry and more than 14 years of experience in the conduct and oversight of clinical trials spanning all phases of cutaneous safety and efficacy studies. Elisabeth oversees the Novella Project Management activities in Europe and is responsible for providing strategic leadership, organisation, training, and ongoing evaluation and support to the Clinical Operations group.
spacer
Dr Elisabeth Rowold
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Recro Gainesville Adds New Facility, Broadens Capabilities With High-Potent Processing on Deck

Gainesville, Ga., Nov. 5, 2018 (Business Wire) – Recro Gainesville has added a 24,000-square-foot facility, which includes high-potent material processing space, near its existing 97,000-square-foot contract pharmaceutical development and manufacturing plant. The company is a wholly owned subsidiary of Recro Pharma, Inc., and a leading provider of solid oral dose development and manufacturing services for the pharmaceutical industry.
More info >>

White Papers

CRSF Label - Child-Resistant Blister Packs With Booklet Label

Faubel & Co. Nachfolger GmbH

This case study explains how Faubel was commissioned by a leading global pharmaceutical company to develop a label for an aluminum blister pack with 14 cavities, which was used as part of a multinational clinical trial. This label was intended to both protect infants from erroneous ingestion and facilitate use by seniors.
More info >>

 
Industry Events

Pre-Filled Syringes & Injectable Drug Devices Europe

16-17 January 2019, Copthorne Tara Hotel, London

SMi is proud to present their 11th annual European conference and exhibition, within the Pre-Filled Syringes series: Pre-Filled Syringes & Injectable Drug Devices Europe. The event will take place on the 16th-17th of January 2019, in London.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement